44.7 percent of angiotensin receptor blocker initiators were continuously persistent to original drug class at three years.

Post hoc trial findings support aprocitentan’s potential cardiovascular and kidney-protective effects in patients with chronic kidney disease (CKD) with resistant hypertension.

The American Association for the Study of Liver Diseases and Infectious Diseases Society of America have updated guidance on ...

SaveHealth reports on 10 hypertension medications, their classifications, effectiveness, side effects, and safety in managing ...

The American Heart Association and the American the College of Cardiology in 2025 issued guidelines to help reduce ...

Despite affecting approximately 1% of the population and carrying significant mortality risk, pulmonary hypertension (PH) remains underrecognized compared to other cardiovascular conditions. Several ...

As more adults develop hypertension at younger ages, with many never reaching recommended treatment goals, updated clinical recommendations are changing how clinicians diagnose, monitor, and manage ...

Treatment options for managing your PH will depend on what type of pulmonary hypertension you have. Each type of pulmonary hypertension requires a tailored treatment plan that follows the latest ...

There is no cure for pulmonary hypertension (PH), but appropriate treatment can slow disease progression, ease symptoms, and improve life quality. In PH, pressure is elevated in the pulmonary arteries ...

“We are working off previous clinical trials that informed guidance on the benefits of maintaining blood pressure for mother and baby,” said Rachel Sinkey, M.D., associate professor in the University ...

Please provide your email address to receive an email when new articles are posted on . AHA and ACC unveiled a companion document to their recently published hypertension guideline. The document ...